Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
21 oct. 2024 09h00 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy
15 oct. 2024 16h05 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
07 oct. 2024 09h00 HE
|
Biomea Fusion, Inc.
BMF-219 is an investigational oral covalent menin inhibitor developed to regenerate insulin-producing beta cells Two trial-in-progress oral presentations to feature Phase II study design of oral...
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
01 oct. 2024 09h00 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
26 sept. 2024 14h00 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and...
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
01 août 2024 16h05 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
31 juil. 2024 16h05 HE
|
Biomea Fusion, Inc.
COVALENT-111 Phase 2b on track for Q4 2024 readoutCOVALENT-112 Phase 2a on track for Q4 2024 readoutAnnouncement of the third program in obesity on track for Q3 2024 REDWOOD CITY, Calif., July 31,...
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
06 juin 2024 16h05 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug...
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
03 juin 2024 16h05 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
30 mai 2024 09h12 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent...